"Put simply, LOXO -305 has exceeded our expectations, " said Jacob Van Naarden, chief operating o fficer of Loxo Oncology at Lilly. "LOXO – 305's wide therapeutic index allows us to plan and implement an ambitious comprehensive development program, one that includes combination regimens that exploit the drug's selectivity profile. We look forward to working closely with global regulators to position LOXO-305 in the most appropriate patient populations. It will be excitin g to combine Lilly's